COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience

Click to increase image sizeClick to decrease image size

Acknowledgments

The authors are indebted to the nursing and research staff involved in these studies and to all the participants and their families.

Disclosure statement

N.M-S has research funding from Bristol Myers-Squibb, Astrazeneca Pharmaceuticals, Celgene, Secura Bio, Verastem, Roche/Genentech, C4 Therapeutics, Corvus, Innate Pharmaceuticals, Daiichi Sankyo. N. M-S has consulted for Secura Bio, Daiichi sankyo, C4 Therapeutics, Karyopharm Therapeutics, Kyowa Hakka Kirin. N.L.B has research funding from ADC Therapeutics, Affimed, Autolus, Bristol-Myers Squibb, Celgene, Forty Seven, Immune Design, Janssen, Kite Pharma/Gilead, Merck, Millennium, Pharmacyclics, Pfizer, Roche/Genentech, and SeaGen, and been on advisory boards for Acerta, ADC Therapeutics, BTG, Roche/Genentech, and SeaGen. B.K has research funding from AcertaPharma/AstraZeneca Group, Astrazeneca Pharmaceuticals LP, BeiGene Ltd., Roche/Genetech, has been on advisory boards for Abbvie, ADC Therapeutics, Astrazeneca Pharmaceuticals LP, Beigne Ltd., Celgene Corporations, Epizyme Inc., Roche/Genetech, Pharmacyclics, LLC an AbbVie Company, Roche Laboratories Inc, TG Therapeutics Inc and has served on the data & safety monitoring board/committee for Celgene Corporations, MEI Pharma Inc., Takeda Oncology. C.W.F has research funding from Abbott Laboratories, Roche Diagnostics, Beckman Coulter, The Binding Site, Siemens Healthineers, has consulted for Roche Diagnostics and has had speaking fees from Roche Diagnostics. S.W. has research funding from AbbVie Inc, Ariad Pharmaceuticals, Genentech, Immunomedics, Inc., Millennium Pharmaceuticals Inc, Roche, Astellas Pharma Inc, Daiichi Sankyo, Cullinan Pearl, Verastem Inc, GlaxoSmithKline/GSK, Janssen Research & Development, LLC, Elevation Oncology, Daiichi Sankyo, Genentech, Loxo Oncology, Takeda Pharmaceuticals Company Limited. S.W. serves on the stat safety monitoring board for Hooiser Cancer Research Network. M.P.W, A.D, C.B., G.S and F.W have no conflicts of interest.

Author contributions

N.M-S and N.L.B provided study design, contributed patients, collected and analyzed data, and prepared the manuscript, B.K. contributed patients, M.P.W collected and analyzed data and prepared the manuscript, A.D and G.S collected and analyzed data, S.W. provided study design, F.W. performed statistical analysis and C.F.W provided study design, collected, generated and analyzed data, and prepared the manuscript. All authors reviewed, edited, and approved the final manuscript.

Additional information

Funding

The authors would like to thank the Barnes-Jewish Hospital Foundation for support. N. M-S is supported by the Lymphoma Research Foundation.